lg1

Doxenitoin is an anticonvulsant agent.

LG100754 (UVI 2112)是一种通过RXR 发挥作用的胰岛素增敏剂。LG100754是RXR 二聚体调节剂。LG100754是RXR:RXR 同二聚体拮抗剂，以及RXR:PPARα和RXR:PPPARγ异二聚体的激动剂。

LG100268是一种强效、选择性和口服活性的视黄醇X受体（RXR）激动剂，以纳摩尔级别激动RXR-α、RXR-β和RXR-γ，选择性超过RAR三个数量级。LG100268能够诱导脂肪细胞中的转录激活；影响RXRs和其伴侣受体Foxl2/Dmrt1诱导比目鱼幼鱼的雄性化；抑制黑脂腺上皮细胞中角蛋白17的表达；在HER2或三阴性乳腺癌中增加PD-L1的表达。

LG190119 is a nonsecosteroidal vitamin D receptor modulator. It effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. It also inhibits the growth of LNCaP xenograft tumors in athymic

LG190178, a vitamin D receptor (VDR) ligand, is a therapeutic agent used for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism.

LG190155 is a moderately potent VDR agonist. Vitamin D receptor (VDR) agonists are well known for their capacity to control calcium and bone metabolism and to regulate growth and differentiation of many cell types.

LG157 is a strong inhibitor of the mitotic kinesin-like protein 2 (MKLP2) [1].

Anti-B7-H6/NCR3LG1 Antibody 是一种靶向 B7-H6/NCR3LG1 的 CHO 表达的人源抗体。它带有 huIgG1 类型的重链和 huκ 类型的轻链，预测的分子量 (MW) 为 150 kDa。

Medifoxamine (LG 152) 是一种选择性非单胺氧化酶抑制剂,通过对5 HT 再摄取的抑制展现其抗抑郁活性。Medifoxamine 优先抑制多巴胺再摄取 (dopamine reuptake)。

IDO-IN-5 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO-IN-6 is an indoleamine 2,3-dioxygenase (IDO) inhibitor.

IDO-IN-8 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

LG-100064 是一种类视黄醇 X 受体激动剂，对 RXRα、RXRβ 和 RXRγ 的 EC50值分别为 330、200 和 260 nM，可用于癌症研究。

RXR modulator

Sorbinicate is an antihypercholesterolaemic and vasodilating nicotinic acid ester.

LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group with orally active. LG-120907 is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM.

LG-121071 is a selective androgen receptor modulator (SARM) with orally active. LG-121071 acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM).

PSB-1901 是一种高度有效且选择性的 A2B 腺苷受体拮抗剂，对人 A2BAR 具有皮摩尔级亲和力，对其他腺苷受体亚型的选择性超过 10,000 倍，同时在小鼠 A2BAR 上保持相当的效力，使其成为研究腺苷介导信号通路的强有力的临床前药理学工具。